MBX Biosciences, Inc. filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission on November 9, 2026, registering 900,000 shares of common stock issuable under its 2026 Inducement Plan.

Key Highlights

  • Shares registered: 900,000 shares of common stock, par value $0.0001 per share, are being registered under the 2026 Inducement Plan.
  • Plan origin: The board of directors adopted the MBX Biosciences, Inc. 2026 Inducement Plan in March 2026, initially reserving 130,000 shares.
  • Reserve increase: Also in March 2026, the board approved an increase in reserved shares from 130,000 to 900,000.
  • Eligible recipients: Awards under the plan are granted exclusively to individuals who were not previously employees or directors of the company, as an inducement to enter employment.
  • Award types: The plan provides for nonqualified stock options, stock options, stock appreciation rights, restricted shares, restricted stock units, dividend equivalent rights, and cash bonuses.
  • No stockholder approval: The plan was adopted by the board without stockholder approval, pursuant to Rule 5635(c)(4) of the Marketplace Rules of the Nasdaq Stock Market.
  • Company status: MBX Biosciences is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

MBX Biosciences Files S-8 to Cover 2026 Inducement Plan Share Grants

According to the filing, MBX Biosciences, Inc. (NASDAQ:MBX), a Delaware corporation headquartered at 11711 N. Meridian Street, Suite 300, Carmel, Indiana 46032, submitted this Registration Statement on Form S-8 to register the offer and sale of 900,000 shares of its common stock, par value $0.0001 per share, issuable to grantees under the MBX Biosciences, Inc. 2026 Inducement Plan.

The filing discloses that the board of directors initially adopted the 2026 Inducement Plan in March 2026 with a reserve of 130,000 shares. In the same month, the board approved increasing the reserved share pool to 900,000. The plan was established under Rule 5635(c)(4) of the Marketplace Rules of the Nasdaq Stock Market, which permits adoption without stockholder approval when awards are used as an inducement material to a new employee's entry into employment with the company. The filing states that awards may only be granted to individuals who were not previously employees or directors of the registrant.

The 2026 Inducement Plan, according to the filing, permits grants of nonqualified stock options, stock options, stock appreciation rights, restricted shares of common stock, restricted stock units, dividend equivalent rights, and cash bonuses. The registration statement incorporates by reference previously filed documents including the company's Annual Report on Form 10-K for the year ended December 31, 2025, Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026, and September 30, 2026, and various Current Reports on Form 8-K. Steven L. Hoerter, Chairman and Chief Executive Officer, is identified as the agent for service in connection with this filing.

What Was Disclosed

MBX Biosciences filed a Form S-8 on November 9, 2026, registering 900,000 shares of common stock under its 2026 Inducement Plan, which was adopted by the board in March 2026 without stockholder approval and is limited to new-hire inducement grants.